Vor Biopharma (VOR) Cash from Operations (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Cash from Operations of 38246000.0 for Q1 2026, down 23.11% year-over-year from 49742536.88 in Q1 2025, and down 67.74% quarter-over-quarter from 22801000.0 in Q4 2025.
Powered by 
Analysis
Vor Biopharma (VOR) Cash from Operations (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Cash from Operations for 7 consecutive years, with 38246000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 23.11% year-over-year to 38246000.0; the TTM figure through Mar 2026 stood at 149893000.0 (down 49.5% YoY), while the FY2025 annual figure was 142713000.0, down 43.2% from the prior year.
- Cash from Operations eased to 38246000.0 in Q1 2026 per VOR's latest filing, from 22801000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 18346000.0 in Q4 2022 and bottomed at 53662000.0 in Q3 2025.
- Historically, Cash from Operations has averaged 27415000.0 across 5 years, with a median of 24100000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations increased 16.54% — and 2025, when it plunged 130.46%.
- Vor Biopharma's Cash from Operations stood at 18346000.0 in 2022, then tumbled by 30.96% to 24026000.0 in 2023, then dropped by 0.15% to 24063000.0 in 2024, then climbed by 5.24% to 22801000.0 in 2025, then slumped by 67.74% to 38246000.0 in 2026.
- Business Quant data shows VOR's Cash from Operations at 38246000.0 in Q1 2026, 22801000.0 in Q4 2025, and 53662000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -25.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.38 Mn |
| Mar 31, 2026 | -38.25 Mn |
| Dec 31, 2025 | -22.80 Mn |
| Sep 30, 2025 | -53.66 Mn |
| Jun 30, 2025 | -35.18 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Dec 31, 2024 | -24.06 Mn |
| Sep 30, 2024 | -23.29 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -30.47 Mn |
| Dec 31, 2023 | -24.03 Mn |
| Sep 30, 2023 | -27.90 Mn |
| Jun 30, 2023 | -24.10 Mn |
| Mar 31, 2023 | -24.27 Mn |
| Dec 31, 2022 | -18.35 Mn |
| Sep 30, 2022 | -18.90 Mn |
| Jun 30, 2022 | -24.99 Mn |
| Mar 31, 2022 | -22.90 Mn |
| Dec 31, 2021 | -17.59 Mn |
| Sep 30, 2021 | -17.34 Mn |